{"entity":{"type":"insider","cik":"0002060075","url":"/insider/0002060075","json_url":"/insider/0002060075.json","name":"Goodman Noah","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":9,"n_filings":5,"first":"2026-04-10","last":"2026-07-02","span_basis":"filed_date"},"name_variants":[{"name":"Goodman Noah","source":"filing","n_filings":5,"first_seen":"2026-04-10","last_seen":"2026-07-02"}],"transactions":[{"id":6202125,"accession":"0001193125-26-295089","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-295089","line_url":"/filing/0001193125-26-295089#line-1","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0002060075","owner_name":"Goodman Noah","owner_display_name":"Goodman Noah","owner_url":"/insider/0002060075","role":"Officer (Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3389.0,"shares_display":"3,389","price_per_share":114.29,"price_display":"114.29","price_state":"stated","total_value":387328.81,"total_display":"387,328.81","total_whole":"387,329","shares_owned_after":47179.438,"shares_owned_after_display":"47,179.44","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-01","filed_date":"2026-07-02","scope":"insider"},{"id":5896979,"accession":"0001193125-26-283139","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193125-26-283139","line_url":"/filing/0001193125-26-283139","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0002060075","owner_name":"Goodman Noah","owner_display_name":"Goodman Noah","owner_url":"/insider/0002060075","role":"Officer (Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":114.0,"price_display":"114.00","price_state":"stated","total_value":570000.0,"total_display":"570,000.00","total_whole":"570,000","shares_owned_after":50195.438,"shares_owned_after_display":"50,195.44","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-25","filed_date":"2026-06-25","scope":"insider","n_lines":2},{"id":5837565,"accession":"0001193125-26-277766","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-26-277766","line_url":"/filing/0001193125-26-277766#line-2","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0002060075","owner_name":"Goodman Noah","owner_display_name":"Goodman Noah","owner_url":"/insider/0002060075","role":"Officer (Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":99.0,"price_display":"99.00","price_state":"stated","total_value":247500.0,"total_display":"247,500.00","total_whole":"247,500","shares_owned_after":50195.438,"shares_owned_after_display":"50,195.44","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-22","filed_date":"2026-06-22","scope":"insider"},{"id":5773343,"accession":"0001193125-26-159539","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-159539","line_url":"/filing/0001193125-26-159539#line-1","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0002060075","owner_name":"Goodman Noah","owner_display_name":"Goodman Noah","owner_url":"/insider/0002060075","role":"Officer (Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1347.0,"shares_display":"1,347","price_per_share":90.0,"price_display":"90.00","price_state":"stated","total_value":121230.0,"total_display":"121,230.00","total_whole":"121,230","shares_owned_after":50195.438,"shares_owned_after_display":"50,195.44","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-14","filed_date":"2026-04-16","scope":"insider"},{"id":5919778,"accession":"0001193125-26-151393","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001193125-26-151393","line_url":"/filing/0001193125-26-151393#line-5","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0002060075","owner_name":"Goodman Noah","owner_display_name":"Goodman Noah","owner_url":"/insider/0002060075","role":"Officer (Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":87.35,"price_display":"87.35","price_state":"stated","total_value":174700.0,"total_display":"174,700.00","total_whole":"174,700","shares_owned_after":51542.438,"shares_owned_after_display":"51,542.44","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-10","filed_date":"2026-04-10","scope":"insider"},{"id":5919776,"accession":"0001193125-26-151393","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-26-151393","line_url":"/filing/0001193125-26-151393","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0002060075","owner_name":"Goodman Noah","owner_display_name":"Goodman Noah","owner_url":"/insider/0002060075","role":"Officer (Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8264.0,"shares_display":"8,264","price_per_share":87.49784547434656,"price_display":"87.50","price_state":"stated","total_value":723082.195,"total_display":"723,082.20","total_whole":"723,082","shares_owned_after":58712.438,"shares_owned_after_display":"58,712.44","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-09","filed_date":"2026-04-10","scope":"insider","n_lines":3}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":9,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":9,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":9},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001815442","name":"Kymera Therapeutics, Inc.","url":"/issuer/0001815442","role":"Officer (Chief Business Officer)","n_filings":5,"first_seen":"2026-04-10","last_seen":"2026-07-02"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0002060075","retrieved_at":"2026-08-22T10:26:14+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}